Bhatt DL, Steg PG, Miller M Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019; 380:(1)11-22

Borén J, Williams KJ The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol. 2016; 27:(5)473-483

London: BHF; 2011

Burgess S, Ference BA, Staley JR Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis. JAMA Cardiol. 2018; 3:(7)619-627

Bytyçi I, Penson PE, Mikhailidis DP Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022; 43:(34)3213-3223

Cannon CP, Blazing MA, Giugliano RP Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372:(25)2387-2397

Cartier LJ, Collins C, Lagacé M, Douville P Comparison of fasting and non-fasting lipid profiles in a large cohort of patients presenting at a community hospital. Clin Biochem. 2018; 52:61-66

Cegla J, Neely RDG, France M HEART UK consensus statement on Lipoprotein(a): A call to action. Atherosclerosis. 2019; 291:62-70

Baigent C, Blackwell L Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376:(9753)1670-1681

Mihaylova B, Emberson J The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012; 380:(9841)581-590

Conroy RM, Pyörälä K, Fitzgerald AP Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24:(11)987-1003

Cooney MT, Dudina A, Whincup P Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies. Eur J Cardiovasc Prev Rehabil. 2009; 16:(5)541-549

Cuchel M, Meagher EA, du Toit Theron H Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013; 381:(9860)40-46

Doran B, Guo Y, Xu J Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). Circulation. 2014; 130:(7)546-553

Downs JR, Clearfield M, Weis S Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998; 279:(20)1615-1622

Durrington PN, 3rd edn.. London: Hodder Arnold; 2017

Durrington PN, Sniderman AAbingdon: Health Press; 2000

Ference BA, Ginsberg HN, Graham I Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38:(32)2459-2472

Ference BA, Graham I, Tokgozoglu L, Catapano AL Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. J Am Coll Cardiol. 2018; 72:(10)1141-1156

Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. 2019.

Jun M, Zhu B, Tonelli M Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2012; 60:(20)2061-2071

Laufs U, Banach M, Mancini GBJ Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. J Am Heart Assoc. 2019; 8:(7)

Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis. 2011; 217:(2)492-498

Mach F, Baigent C, Catapano AL 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41:(1)111-188

Moriarty PM, Thompson PD, Cannon CP Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015; 9:(6)758-769

Musa-Veloso K, Poon TH, Elliot JA, Chung C A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo-controlled trials. Prostaglandins Leukot Essent Fatty Acids. 2011; 85:(1)9-28

National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. 2016a. (accessed 20 September 2022)

National Institute for Health and Care Excellence. Ezetimibe for treating primary heterozygous familial and non-familial hypercholesterolaemia. 2016b. (accessed 26 September 2022)

National Institute for Health and Care Excellence. Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia. 2021a. (accessed 20 September 2022)

National Institute for Health and Care Excellence. Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia. 2021b. (accessed 20 September 2022)

National Institute for Health and Care Excellence. Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides. 2022. (accessed 20 September 2022)

Nordestgaard BG, Langsted A Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016; 57:(11)1953-1975

Nozue T Lipid Lowering Therapy and Circulating PCSK9 Concentration. J Atheroscler Thromb. 2017; 24:(9)895-907

Phan BA, Dayspring TD, Toth PP Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012; 8:415-427

Pottle A Lipid disorders and familial hypercholesterolaemia. In: Llahana S, Follin C, Yedinak C, Grossman A Switzerland: Springer; 2019

Raal FJ, Kallend D, Ray KK Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020; 382:(16)1520-1530

Ray KK, Wright RS, Kallend D Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020; 382:(16)1507-1519

Rubino J, MacDougall DE, Sterling LR, Hanselman JC, Nicholls SJ Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial. Atherosclerosis. 2021; 320:122-128

PCSK9 inhibitors: what we know, what we should have understood, and what is to come. 2019.

Sabatine MS, Giugliano RP, Keech AC Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376:(18)1713-1722

Schwartz GG, Steg PG, Szarek M Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018; 379:(22)2097-2107

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Survival Study. Lancet. 1994; 344:1383-1389

Stroes E, Colquhoun D, Sullivan D Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014; 63:(23)2541-2548

Stroes ES, Thompson PD, Corsini A Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015; 36:(17)1012-1022

Tabas I, Williams KJ, Borén J Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007; 116:(16)1832-1844

Thompson GR HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008; 198:(2)247-255

Tokgozoglu L, Canpolat U Can cardiac rehabilitation improve LDL-cholesterol target attainment after acute coronary syndromes?. Eur J Prev Cardiol. 2019; 26:(3)246-248

Toth PP, Patti AM, Giglio RV Management of statin intolerance in 2018: still more questions than answers. Am J Cardiovasc Drugs. 2018; 18:(3)157-173

Townsend N, Nichols M, Scarborough P, Rayner M Cardiovascular disease in Europe–epidemiological update 2015. Eur Heart J. 2015; 36:(40)2696-2705

Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med. 2020; 382:(3)244-255

Visseren FLJ, Mach F, Smulders YM 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42:(34)3227-3337

Cholesterol: how to measure and how to treat

02 October 2022
Volume 33 · Issue 10


Raised lipid levels are a significant risk factor for cardiovascular disease. Alison Pottle provides an overview of how these are measured and the lifestyle measures and medications that can be used to reduce risk in these patients

Cardiovascular disease (CVD) is the leading cause of death in England and Wales. Raised lipid levels are a significant risk factor for CVD. Lipids are a heterogeneous group of substances which include cholesterol, triglycerides, lipoproteins and apolipoproteins. The link between increased lipid levels and atherosclerosis was first established in the early 1900s. Numerous clinical studies have demonstrated the critical role of low density lipoproteins and other cholesterol-rich apolipoprotein-B containing lipoproteins in atherosclerotic plaque formation and the subsequent risk of CVD events. There is now clear indication that the lower the achieved LDL levels, the lower the risk of CVD. Multiple interventions including changes in lifestyle together with the use of lipid-lowering therapies may be required to achieve desired lipid levels, and practice nurses can play a key role in this. This article will discuss how cholesterol levels are measured and the treatment strategies now available.

Cardiovascular disease (CVD), of which atherosclerotic cardiovascular disease (ASCVD) is the major component, is responsible for more than 4 million deaths in Europe annually (Mach et al, 2020). It is the cause of death for more women than men (2.2 million versus 1.8 million), although CV deaths before the age of 65 years are more common in men than in women (490 000 versus 193 000) (Townsend et al, 2015). The major risk factors for ASCVD, which have been identified over the past few decades, are blood apolipoprotein-B (APO-B) containing lipoproteins (predominately low-density-lipoproteins [LDL]), elevated blood pressure, cigarette smoking and diabetes mellitus (Visseren et al, 2021). Prevention is defined as a co-ordinated set of actions aimed at eliminating or minimising the impact of CVD and related disabilities (Mach et al, 2020). The importance of ASCVD prevention remains undisputed and needs to be delivered at a general population level by promoting healthy lifestyle behaviour (Cooney et al, 2009), and at an individual level by tackling unhealthy lifestyles and by reducing increased levels of causal risk factors such as cholesterol. Practice nurses have a key role to play in this.

Register now to continue reading

Thank you for visiting Practice Nursing and reading some of our peer-reviewed resources for general practice nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • New content and clinical newsletter updates each month